LONDON (Reuters) -Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff wars, hoping to avert price spikes on top-selling medicines ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Event summary produced by The Globe and Mail Events team. The Globe’s editorial department was not involved.

Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Nvidia shares have been under pressure since late January, when the release of a lower cost artificial intelligence (AI) model by Chinese startup DeepSeek prompted a sharp fall in the stock. The ...

Four companies have applied to Health Canada to sell copies of Ozempic after its market exclusivity expires on Jan. 4, 2026 ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

European markets closed lower as global markets buckle amid anxiety that the U.S. economy will suffer because of Trump’s ...

Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents ...

Here are the most important news items that investors need to start their trading day: ...

Novo Nordisk (NVO) warns U.S. tariffs on pharmaceuticals may lead to drug shortages & price hikes. Read more here.